2) This program, intended for #healthcare providers, includes updates from #ESMO22 @myESMO
— @onc_ce (@onc_ce) March 30, 2023
It is supported by an independent educational grant from AstraZeneca. Statement of accreditation and faculty disclosures are at https://t.co/8oShcATovC.
3b) It's d = a & c. Anti-PD-1/PD-L1 and anti-CTLA-4 agents act at different parts of the cancer immunity cycle. Combining these agents is synergistic and could help overcome resistance to single-agent immunotherapy. pic.twitter.com/AQjb7Ggm2X
— @onc_ce (@onc_ce) March 30, 2023
5) For patients with high #PD_L1 expression (more than 50%), the use of #ICIs in #monotherapy improved significantly all the efficacy endpoints, when compared with standard chemotherapy ➡️5-year survival rate never seen before in #thoracic #oncology#LCSM pic.twitter.com/g1fI1AeM67
— @onc_ce (@onc_ce) March 30, 2023
7) Trials evaluating different ICIs (e.g. #pembrolizumab #atezolizumab #cemiplimab) showed significant improvement in #mNSCLC, regardless the PD-L1 valued, with improved rate of long-term survival (2/3/5 yrs survival), not achieved before in this setting https://t.co/Td1POVoQaF
— @onc_ce (@onc_ce) March 30, 2023
9) Two similar strategies were developed to investigate the role of #platinum-based #chemo, plus #PD1/PD-L1 and anti-#CTLA4 in different phase 3 trials: the #CheckMate-9La and the #POSEIDON trial. pic.twitter.com/SqAgbrHGiX
— @onc_ce (@onc_ce) March 30, 2023
10b) Clinical benefit with NIVO + IPI + chemo vs chemo was observed in all randomized pts and across most subgroups, including by #PD_L1 expression level or histology. pic.twitter.com/5F59QLrl4k
— @onc_ce (@onc_ce) March 30, 2023
12a) In the POSEIDON trial, the combo arm with chemo + durva + #tremilimumab, showed a trend for OS benefit confirmed in:
— @onc_ce (@onc_ce) March 30, 2023
1)STK11m, KEAP1m or KRASm
2)PI3Kim
3)EGFR and ALK positive
4)P53+
13a) #Bispecific antibodies are a promising approach in immuno-oncology that combines the potential benefits of two medicines into one antibody without the increased toxicity seen with administration of two separate medicines.
— @onc_ce (@onc_ce) March 30, 2023
14) #MEDI5752 showed ⬆️antitumour activity w/ doubling of the DoR vs #pembrolizumab + CT, in non-squamous NSCLC, w/ a mPFS and mOS numerically superior to that of #pembrolizumab + CT in the randomised cohorts, with a confirmed benefit in pts with tumor PD-L1 <1% (#ESMO22 LBA56) pic.twitter.com/mBkQCDRsEr
— @onc_ce (@onc_ce) March 30, 2023
15b) Looking forward, major advances in the management of #mNSCLC are expected, thanks to new #ICIs under evaluation in clinical trials, such as #MEDI5752. pic.twitter.com/cHIF3tUztl
— @onc_ce (@onc_ce) March 30, 2023
16) You need look no further, though, to collect your 0.5hr 🆓CE/#CME! Just point your 🖱️to https://t.co/SbAz1QtYhs to claim your certificate. And FOLLOW US here on @onc_ce for more expert-led education on advances in #oncology! @APassaroMD 🙏you for joining us. Hurry back!
— @onc_ce (@onc_ce) March 30, 2023